CENCORA, INC. FY 2025 10-K, explained in plain English

COR · 10-K for the period ending September 30, 2025, filed November 25, 2025 · Read the original on SEC.gov →

Key financials — as reported

Total revenue	$321.3B
Gross margin	3.6%
Operating income	$2.6B
Net income	$1.6B
Diluted EPS	$7.96
Cash & equivalents	$4.4B
Total assets	$76.6B
Long-term debt	$7.7B

Key takeaway

Cencora reported $321.3 billion in fiscal 2025 revenue but operated on a thin 3.6% gross margin typical of pharmaceutical distribution.

🔒 4 more takeaways in the full analysis

Beneath the surface

The $723.9 million PharmaLex goodwill impairment materially depressed operating income and reflects a strategic misstep in the life sciences services expansion.

🔒 4 more insights a headline reader would miss

This is the free preview. The full analysis explains every line item above and includes 8 more findings — plus insider trades, activist stakes, and 8-K events for COR.

Read the full analysis free Free account · 5 full analyses included · no card required